NSILICO LIFESCIENCE
NSilico is a bioinformatics software development company based in Dublin and Cork, Ireland.
NSILICO LIFESCIENCE
Industry:
Biotechnology Health Diagnostics Software
Address:
Dublin, Dublin, Ireland
Country:
Ireland
Website Url:
http://www.nsilico.com
Total Employee:
1+
Status:
Active
Contact:
+353 21 234 0232
Email Addresses:
[email protected]
Similar Organizations
More informations about "NSilico Lifescience"
Insilico Medicine - Wikipedia
Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery. See moreSee details»
Main
Our mission is to extend healthy productive longevity by transforming drug discovery and development with generative artificial intelligence, significantly reducing the time and cost to bring life-saving medications to patients. …See details»
Mission | Insilico Medicine
We are a globally leading end-to-end generative AI-driven biotech company in terms of AIDD pipeline progress, with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary Pharma.AI …See details»
Team | Insilico Medicine
, is the founder and CEO of Insilico Medicine (insilico.com), a leader in generative artificial intelligence technologies for drug discovery and biomarker development. Dr. Zhavoronkov has …See details»
Insilico Medicine - Crunchbase Company Profile & Funding
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. Insilico Medicine may be growing as evidenced by several indicators. The company …See details»
Insilico Medicine Signs Strategic Research Collaboration
Nov 8, 2022 · Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next …See details»
Insilico Medicine Reports Positive Phase IIa Results for ISM001 …
CAMBRIDGE, Mass., Sept. 18, 2024 /PRNewswire/ -- Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its …See details»
Insilico Medicine Uses Generative AI to Accelerate Drug Discovery ...
Jun 27, 2023 · Insilico used generative AI for each step of the preclinical drug discovery process: to identify a molecule that a drug compound could target, generate novel drug candidates, …See details»
AI drug discovery platform Insilico Medicine announces $255 …
Jun 22, 2021 · Insilico Medicine, an AI-based platform for drug development and discovery, announced $255 million in Series C financing on Tuesday.See details»
Insilico Medicine named Top Biotech Company i | EurekAlert!
Mar 19, 2024 · Insilico Medicine (“Insilico”), a clinical stage artificial intelligence (AI)-driven drug discovery company, has been named the top biotech company in Fast Company’s 2024 …See details»
Insilico Medicine Reports Positive Phase IIa Results for ISM001 …
Sep 18, 2024 · ISM001-055 is a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase) and was designed utilizing generative AI to treat idiopathic pulmonary …See details»
Insilico Medicine leverages generative AI and | EurekAlert!
Aug 2, 2023 · Insilico Medicine (“Insilico”), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has achieved a significant breakthrough in the …See details»
Insilico Medicine Reports Positive Phase IIa Results for IPF
Sep 19, 2024 · Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055.See details»
Insilico Medicine - Funding, Financials, Valuation & Investors
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.See details»
Insilico’s AI Pipeline for Drug Discovery To Grow with New …
Nov 11, 2020 · On November 10th, Insilico Medicine, a leader in AI technology and reinforcement learning for target discovery, entered into a multi-target drug discovery agreement with …See details»
Forbidden DevelopmentAid
NSilico Life Science Limited — Consulting Organization from Ireland, has experience with Horizon 2020 (2014 - 2020), it`s involved in Health, Information & Communication Technology, …See details»
From Start to Phase 1 in 30 Months | Insilico Medicine
We are thrilled to announce that we have successfully completed a Phase 0 clinical study and entered a Phase I clinical trial with our first-in-class anti-fibrotic drug candidate for a novel …See details»
Credibility assessment of in silico clinical trials for medical devices
Aug 8, 2024 · In silico clinical trials (ISCTs) are an emerging method in computational modeling and simulation (M&S) where medical interventions are evaluated using a range of …See details»
Insilico Medicine and Sanofi Report AI-Enabled Milestone in Drug ...
Oct 31, 2024 · Insilico Medicine and Sanofi achieve a key milestone in AI-driven oncology drug discovery, advancing a first-in-class lead molecule targeting an undruggable transcription …See details»
Pipeline | Insilico Medicine
Programs below progressed beyond early pre-clinical. Many programs are available under CDA. The rapid progress of internal pipeline demonstrates the generative-AI driven drug discovery …See details»